Skip to main content
Toggle navigation
FR
EN
Drupal
Main navigation EN
About Crossject
Who we are
Governance
R&D
Our technology
ZENEO®: needle-free technology
Products under development
Our supply chain
Therapeutic areas
Migraines and cluster headaches
Anaphylactic shock
Acute adrenal crisis
Epileptic seizure
Opioid overdose
Rheumatoid arthritis
Severe asthma crisis
Main navigation 2 EN
Finances
Profile
Analyst coverage
Financial releases
News
Our news
Press releases
Careers
Working at Crossject
Available position and applications
Contact
Search
Search
Enter the terms you wish to search for.
Home
Finances
Financial releases
Financial releases
Release date
Min
Max
Year
All
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
Apply
2023/09/26
Crossject reports financial results and business highlights for first half of 2023
Read the release
2023/09/11
Crossject announces significant improvement in Gaïa ESG rating
Read the release
2023/09/05
Crossject reports successful completion of European and U.S. audits for manufacturing of ZENEO® Midazolam for epileptic seizures
Read the release
2023/07/20
Crossject signs new licensing agreement on ZENEO® Midazolam epilepsy rescue therapy with AFT Pharmaceuticals for Australia & New Zealand
Read the release
2023/06/01
Appointment of Daniel Teper to the Crossject Supervisory Board - Building skills to support the US transition
Read the release
2023/03/20
2022 Annual Results
Read the release
2023/01/13
Further strengthening of the financial structure
Read the release
2022/11/07
Big improvement in the Gaïa social and environmental rating
Read the release
2022/11/02
Clinical demonstration of ZENEO® efficiency for intramuscular injection of midazolam
Read the release
2022/09/22
First-half 2022 results Achievement of major milestones in the first half On track for a change of dimension
Read the release
Pagination
Current page
1
Page
2
Page
3
Page
4
Page
5
Page
6
Page
7
Page
8
Next page
Next ›
Last page
Last »
